Halal Stock Search
Unlockmore than 90 stock exchanges for FREE
{{companyExchange}}
| Company Name |
| Company Symbol |
| Exchange |
| Ocugen |
| OCGN |
| NASDAQ |
Warning: The result may change based on other methodologies. As of the recent update on Wednesday 17th of July 2024 , is considered as Halal based on FTSE methodology. To access full report and unlock the detailed results with associated ratios for 5 halal investment methodologies, you can click below.
| Main Activity |
| Activity test result |
| Biotechnology & Medical Research |
| PASS |
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).
| Total Debt |
| Interest free debt |
| Adjusted debt level |
| Total Asset |
| Debt Ratio |
| PASS or FAIL |
| 6476560 |
| 0 |
| 6476560 |
| 74690000 |
| 8.67% |
| PASS |
| Cash |
| Cash Eq. |
| Short Term Investment |
| Total Asset |
| Cash & Eq. ratio |
| PASS or FAIL |
| 0 |
| 53480000 |
| 0 |
| 74690000 |
| 71.6% |
| FAIL |
| Cash |
| Cash Eq. |
| Net Accounts Receivables |
| Total Asset |
| Quick ratio |
| PASS or FAIL |
| 0 |
| 53480000 |
| 0 |
| 74690000 |
| 71.6% |
| FAIL |
Net Interest Income (Expense) as non-Operating
| Total Non permissible and doubtful income |
| Total revenue |
| Non permissible and doubtful income ratio |
| PASS or FAIL |
| 0 |
| 1010000 |
| 0% |
| PASS |